mTOR Inhibitors Control the Growth of EGFR Mutant Lung Cancer Even after Acquiring Resistance by HGF

Resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib, is a critical problem in the treatment of EGFR mutant lung cancer. Several mechanisms, including bypass signaling by hepatocyte growth factor (HGF)-triggered Met activation, are implicated...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishikawa, Daisuke, Takeuchi, Shinji, Nakagawa, Takayuki, Sano, Takako, Nakade, Junya, Nanjo, Shigeki, Yamada, Tadaaki, Ebi, Hiromichi, Zhao, Lu, Yasumoto, Kazuo, Nakamura, Takahiro, Matsumoto, Kunio, Kagamu, Hiroshi, Yoshizawa, Hirohisa, Yano, Seiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653905/
https://www.ncbi.nlm.nih.gov/pubmed/23690929
http://dx.doi.org/10.1371/journal.pone.0062104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653905/
https://www.ncbi.nlm.nih.gov/pubmed/23690929
http://dx.doi.org/10.1371/journal.pone.0062104

Ejemplares similares